Neumora Therapeutics, Inc. SEC filings NMRA
Neumora Therapeutics, Inc. has 258 filings in SEC EDGAR's recent list, going back to Nov 8, 2021. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 30, 2026 | Oct 26, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Other events
|
Jul 27, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Material agreement, New debt, Exit or restructuring costs, Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 27, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEF 14A | Proxy statement | Apr 17, 2026 | May 27, 2026 |
| S-8 | Employee stock plan registration | Mar 30, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 11, 2026 | Feb 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Other events
|
Jan 5, 2026 | Jan 5, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Nov 21, 2025 | Nov 17, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Other events
|
Oct 27, 2025 | Oct 27, 2025 |
| 8-K |
Current report
Other events
|
Oct 27, 2025 | Oct 27, 2025 |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 30, 2025 | May 28, 2025 |
| DEFA14A | Additional proxy material | May 16, 2025 | — |
| 8-K |
Current report
Listing notice
|
May 16, 2025 | May 14, 2025 |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | May 28, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2025 | May 28, 2025 |
| 8-K/A |
Amended current report
Officer or director change
|
Apr 11, 2025 | Feb 13, 2025 |
| EFFECT | Filing | Mar 26, 2025 | — |
| S-8 | Employee stock plan registration | Mar 3, 2025 | — |
| POS AM | Filing | Mar 3, 2025 | — |
| 10-K | Annual report | Mar 3, 2025 | Dec 31, 2024 |
| POSASR | Filing | Mar 3, 2025 | — |
| 8-K |
Current report
Results of operations
|
Mar 3, 2025 | Mar 3, 2025 |
| 8-K/A |
Amended current report
Officer or director change
|
Feb 21, 2025 | Feb 13, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 13, 2025 | Feb 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Other events
|
Jan 2, 2025 | Jan 2, 2025 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| S-3ASR | Automatic shelf registration | Oct 1, 2024 | — |
| 10-Q | Quarterly report | Aug 6, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 13, 2024 |
| 10-Q | Quarterly report | May 7, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 7, 2024 | May 7, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Other events
|
Apr 15, 2024 | Apr 15, 2024 |
| S-8 | Employee stock plan registration | Mar 7, 2024 | — |
| 10-K | Annual report | Mar 7, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 7, 2024 | Mar 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Other events
|
Nov 28, 2023 | Nov 27, 2023 |
| 10-Q | Quarterly report | Nov 1, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 1, 2023 | Nov 1, 2023 |
| S-8 | Employee stock plan registration | Sep 20, 2023 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Sep 19, 2023 | Sep 19, 2023 |
| 424B4 | Prospectus | Sep 18, 2023 | — |
| EFFECT | Filing | Sep 14, 2023 | — |
| SEC STAFF LETTER | Filing | Sep 14, 2023 | — |
| CERT | Filing | Sep 14, 2023 | — |
| 8-A12B | Filing | Sep 13, 2023 | — |
| CORRESP | Letter to the SEC | Sep 12, 2023 | — |
| CORRESP | Letter to the SEC | Sep 12, 2023 | — |
| S-1/A | Amended registration statement | Sep 11, 2023 | — |
| CORRESP | Letter to the SEC | Aug 25, 2023 | — |
| S-1 | Registration statement | Aug 25, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2023 | — |
| DRS/A | Filing | Aug 9, 2023 | — |
| DRSLTR | Filing | Aug 8, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2023 | — |
| DRSLTR | Filing | Jun 30, 2023 | — |
| DRS/A | Filing | Jun 30, 2023 | — |
| SEC STAFF LETTER | Filing | May 24, 2023 | — |
| UPLOAD | Letter from the SEC | May 24, 2023 | — |
| DRS/A | Filing | May 2, 2023 | — |
| D | Filing | Jan 3, 2023 | — |
| DRSLTR | Filing | Sep 2, 2022 | — |
| DRS/A | Filing | Sep 2, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2022 | — |
| DRSLTR | Filing | Jun 10, 2022 | — |
| DRS/A | Filing | Jun 10, 2022 | — |
| UPLOAD | Letter from the SEC | May 16, 2022 | — |
| DRS/A | Filing | May 2, 2022 | — |
| DRS/A | Filing | Feb 14, 2022 | — |
| DRSLTR | Filing | Feb 11, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 7, 2022 | — |
| DRS/A | Filing | Dec 23, 2021 | — |
| DRSLTR | Filing | Dec 22, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 6, 2021 | — |
| DRS | Filing | Nov 8, 2021 | — |
Showing 96 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- NMRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1885522
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.